New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
13:47 EDTREGN, SNYRegeneron price target raised to $382 from $362 at Roth Capital
Roth Capital raised its price target on Regeneron (REGN) after the company and partner Sanofi (SNY) presented the full data set from the ODYSSEY MONO study, along with data supporting the potential for once per month dosing with alirocumab. Roth noted that Sanofi is guiding to filing for approval for the drug in 2016.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
19:26 EDTREGNRegeneron initiated with an Outperform at Raymond James
Subscribe for More Information
10:02 EDTREGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
08:14 EDTREGNRegeneron downgraded to Neutral from Buy at Chardan
Subscribe for More Information
07:45 EDTREGNRegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
06:35 EDTREGN, SNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTREGN, SNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
08:01 EDTREGN, SNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTREGN, SNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 25, 2015
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTREGNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use